Computational Modeling of Drug Disposition

Computer Applications in Pharmaceutical Research and Development

Volumn , Issue , 2006, Pages 495-512

  Chang, Cheng ^a   Swaan, Peter W ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Computational modeling of drug disposition; Data quality ADMET limiting factor; Drug absorption and drug distribution

Indexed keywords

EID: 33751262847     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470037237.ch20     Document Type: Chapter

References (71)

1. Ekins S, Nikolsky Y and Nikolskaya T. Techniques: Application of systems biology to absorption, distribution, metabolism, excretion, and toxicity. Trends Pharmacol Sci 2005;26:202-9.
2. van de Waterbeemd H and Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2003;2:192-204.
3. Martin YC, Bures MG, Danaher EA, DeLazzer J, Lico I and Pavlik PA. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J Comput Aided Mol Des 1993;7:83-102.
4. Jones G, Willett P and Glen RC. A genetic algorithm for fl exible molecular overlay and pharmacophore elucidation. J Comput Aided Mol Des 1995;9:532-49.
5. Clement OO and Mehl AT. HipHop: pharmacophore based on multiple commonfeature alignments. In: Guner OF, editor, Pharmacophore perception, development, and use in drug design. San Diego: IUL, 2000. pp. 69-84.
6. Patel Y, Gillet VJ, Bravi G and Leach AR. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J Comput Aided Mol Des 2002;16:653-81.
7. Schneidman-Duhovny D, Nussinov R and Wolfson HJ. Predicting molecular interactions in silico: II. Protein-protein and protein-drug docking. Curr Med Chem 2004;11:91-107.
8. Cruciani G, Pastor M and Guba W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 2000;11 Suppl 2:S29-39.
9. Eros D, Keri G, Kovesdi I, Szantai-Kis C, Meszaros G and Orfi L. Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods. Mini Rev Med Chem 2004;4:167-77.
10. Yang G, Ran Y and Yalkowsky SH. Prediction of the aqueous solubility: comparison of the general solubility equation and the method using an amended solvation energy relationship. J Pharm Sci 2002;91:517-33.
11. Butina D and Gola JM. Modeling aqueous solubility. J Chem Inf Comput Sci 2003;43:837-41.
12. Delaney JS. ESOL: estimating aqueous solubility directly from molecular structure. J Chem Inf Comput Sci 2004;44:1000-5.
13. Lombardo F, Gifford E and Shalaeva MY. In silico ADME prediction: data, models, facts and myths. Mini Rev Med Chem 2003;3:861-75.
14. Refsgaard HH, Jensen BF, Brockhoff PB, Padkjaer SB, Guldbrandt M and Christensen MS. In silico prediction of membrane permeability from calculated molecular parameters. J Med Chem 2005;48:805-11.
15. Fujikawa M, Ano R, Nakao K, Shimizu R and Akamatsu M. Relationships between structure and high-throughput screening permeability of diverse drugs with artifiial membranes: application to prediction of Caco-2 cell permeability. Bioorg Med Chem 2005;13:4721-32.
16. Artursson P and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991;175:880-5.
17. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 1999;88:28-33.
18. Malkia A, Murtomaki L, Urtti A and Kontturi K. Drug permeation in biomembranes:in vitro and in silico prediction and infl uence of physicochemical properties. Eur J Pharm Sci 2004;23:13-47.
19. Agoram B, Woltosz WS and Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50 Suppl 1:S41-67.
20. Yu LX, Lipka E, Crison JR and Amidon GL. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev 1996;19:359-76.
21. Lombardo F, Obach RS, Shalaeva MY and Gao F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J Med Chem 2002;45:2867-76.
22. Lombardo F, Obach RS, Shalaeva MY and Gao F. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leaveclass- out statistics. J Med Chem 2004;47:1242-50.
23. Colmenarejo G, Alvarez-Pedraglio A and Lavandera JL. Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem 2001;44:4370-8.
24. Kratochwil NA, Huber W, Muller F, Kansy M and Gerber PR. Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol 2002;64:1355-74.
25. Lobell M and Sivarajah V. In silico prediction of aqueous solubility, human plasma protein binding and volume of distribution of compounds from calculated pKa and AlogP98 values. Mol Divers 2003;7:69-87.
26. Mager DE and Jusko WJ. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci 2002;91:2441-51.
27. Yamazaki K and Kanaoka M. Computational prediction of the plasma proteinbinding percent of diverse pharmaceutical compounds. J Pharm Sci 2004;93:1480-94.
28. Cabrera MA, Bermejo M, Perez M and Ramos R. TOPS-MODE approach for the prediction of blood-brain barrier permeation. J Pharm Sci 2004;93:1701-17.
29. Ecker GF and Noe CR. In silico prediction models for blood-brain barrier permeation. Curr Med Chem 2004;11:1617-28.
30. Li H, Yap CW, Ung CY, Xue Y, Cao ZW and Chen YZ., Effect of selection of molecular descriptors on the prediction of blood-brain barrier penetrating and nonpenetrating agents by statistical learning methods. J Chem Inf Model 2005;45:1376-1384.
31. Narayanan R and Gunturi SB. In silico ADME modelling: prediction models for blood-brain barrier permeation using a systematic variable selection method. Bioorg Med Chem 2005;13:3017-28.
32. Subramanian G and Kitchen DB. Computational models to predict blood-brain barrier permeation and CNS activity. J Comput Aided Mol Des 2003;17:643-64.
33. Pardridge WM, Log(BB). PS products and in silico models of drug brain penetration. Drug Discov Today 2004;9:392-3.
34. Abraham MH. The factors that infl uence permeation across the blood-brain barrier. Eur J Med Chem 2004;39:235-40.
35. Liu X, Tu M, Kelly RS, Chen C and Smith BJ. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos 2004;32:132-9.
36. Goodwin JT and Clark DE., In silico predictions of blood-brain barrier penetration:considerations to "keep in mind". J Pharmacol Exp Ther 2005.
37. Taylor EM. The impact of effl ux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002;41:81-92.
38. Toutain PL and Bousquet-Melou A. Plasma clearance. J Vet Pharmacol Ther 2004;27:415-25.
39. Ito K and Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 2005;22:103-12.
40. Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ and Sugiyama Y. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol Pharmacol 2004;66:450-9.
41. Chang C, Ray A and Swaan P. In silico strategies for modeling membrane transporter function. Drug Discov Today 2005;10:663-71.
42. Lin JH and Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98.
43. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94:2031-5.
44. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999;16:1206-12.
45. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz E, Lan LB, et al. Application of three dimensional quantitative structure-activity relationships of Pglycoprotein inhibitors and substrates. Mol Pharmacol 2002;61:974-981.
46. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, et al. Threedimensional quantitative structure-activity relationships of inhibitors of Pglycoprotein. Mol Pharmacol 2002;61:964-73.
47. Pajeva IK and Wiese M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J Med Chem 2002;45:5671-5686.
48. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, et al. Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res 2003;20:1794-803.
49. Cianchetta G, Singleton RW, Zhang M, Wildgoose M, Giesing D, Fravolini A, et al. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. J Med Chem 2005;48:2927-35.
50. Langer T, Eder M, Hoffmann RD, Chiba P and Ecker GF. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model. Arch Pharm (Weinheim) 2004;337:317-27.
51. Mao Q and Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005;7:E118-33.
52. Zhang S, Yang X, Coburn RA and Morris ME. Structure activity relationships and quantitative structure activity relationships for the fl avonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 2005;70:627-39.
53. Aymerich I, Duflot S, Fernandez-Veledo S, Guillen-Gomez E, Huber-Ruano I, Casado FJ, et al. The concentrative nucleoside transporter family (SLC28): new roles beyond salvage? Biochem Soc Trans 2005;33:216-9.
54. Viswanadhan VN, Ghose AK and Weinstein JN. Mapping the binding site of the nucleoside transporter protein: a 3D-OSAR study. Biochim Biophys Acta 1990;1039:356-66.
55. Chang C, Swaan PW, Ngo LY, Lum PY, Patil SD and Unadkat JD. Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol 2004;65:558-70.
56. Hu H, Endres CJ, Chang C, Umapathy NS, Lee EW, Fei YJ, et al. Electrophysiological Characterization and Modeling of the Structure Activity Relationship of the Human Concentrative Nucleoside Transporter 3 (hCNT3). Mol Pharmacol 2006; in press.
57. Snyder NJ, Tabas LB, Berry DM, Duckworth DC, Spry DO and Dantzig AH. Structure-activity relationship of carbacephalosporins and cephalosporins: antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells. Antimicrob Agents Chemother 1997;41:1649-57.
58. Leibach FH and Ganapathy V. Peptide transporters in the intestine and the kidney. Annu Rev Nutr 1996;16:99-119.
59. Ekins S, Johnston JS, Bahadduri P, D'Souza VM, Ray A, Chang C, et al. In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res 2005;22:512-7.
60. Baringhaus KH, Matter H, Stengelin S and Kramer W. Substrate specificity of the ileal and the hepatic Na+/bile acid cotransporters of the rabbi. II. A reliable 3D QSAR pharmacophore model for the ileal Na+/bile acid cotransporter. J Lipid Res 1999;40:2158-68.
61. Swaan PW, Szoka FC, Jr. and Oie S. Molecular modeling of the intestinal bile acid carrier: a comparative molecular field analysis study. J Comput Aided Mol Des 1997;11:581-8.
62. Wright SH and Dantzler WH. Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 2004;84:987-1049.
63. Bednarczyk D, Ekins S, Wikel JH and Wright SH. Infl uence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol 2003;63:489-98.
64. Suhre WM, Ekins S, Chang C, Swaan PW and Wright SH. Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol 2005;67:1067-77.
65. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identifiation and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000;273:251-60.
66. Chang C, Pang KS, Swaan PW, Ekins S. Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther 2005; 314:533-41.
67. Yarim M, Moro S, Huber R, Meier PJ, Kaseda C, Kashima T, et al. Application of QSAR analysis to organic anion transporting polypeptide 1a5 (Oatp1a5) substrates. Bioorg Med Chem 2005;13:463-71.
68. Allen DD and Smith QR. Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J Neurochem 2001;76:1032-41.
69. Geldenhuys WJ, Lockman PR, McAfee JH, Fitzpatrick KT, Van der Schyf CJ and Allen DD. Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. Bioorg Med Chem Lett 2004;14:3085-92.
70. Zhang EY, Phelps MA, Cheng C, Ekins S and Swaan PW. Modeling of active transport systems. Adv Drug Deliv Rev 2002;54:329-54.
71. Zmuidinavicius D, Didziapetris R, Japertas P, Avdeef A and Petrauskas A. Classification structure-activity relations (C-SAR) in prediction of human intestinal absorption. J Pharm Sci 2003;92:621-33.